Compare BRNX & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRNX | EOCN |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.6M |
| IPO Year | 2022 | 2013 |
| Metric | BRNX | EOCN |
|---|---|---|
| Price | $1.06 | $3.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 107.7K | 6.0K |
| Earning Date | 09-09-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35,081.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $2.67 |
| 52 Week High | $10.36 | $3.80 |
| Indicator | BRNX | EOCN |
|---|---|---|
| Relative Strength Index (RSI) | 31.29 | 38.68 |
| Support Level | N/A | N/A |
| Resistance Level | $2.49 | $3.80 |
| Average True Range (ATR) | 0.17 | 0.24 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 15.09 | 39.58 |
BrenX Ltd is reshaping industrial energy to make it cleaner, more reliable, and lower cost. Building on its proprietary bGen thermal energy storage technology, which converts electricity and recovered heat into dispatchable energy, BrenX develops, owns, operates, and optimizes energy assets that serve industrial customers and data centers. From local generation and storage to grid connectivity and intelligent energy management, BrenX brings together technologies and infrastructure to create complete energy platforms around customer needs, with flexible energy assets designed to meet growing energy demand.
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.